Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed diagnosis of inoperable stage IIIB or IV primary pulmonary nonsquamous NSCLC (according to UICC staging valid until 2008) * Sufficient representative sample material for KRAS analysis * Wild-type KRAS * Informed consent of the patient * Aged at least 18 years * WHO Performance Status 0-2 * At least one unidimensional, measurable tumour parameter according to RECIST * Life expectancy of al least 12 weeks * Adequate haematological, hepatic, renal and metabolic function parameters: * Leukocytes \> 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Creatinine clearance ≥ 50 ml/min and serum creatinine ≤ 1.5 x upper limit of normal * Bilirubin ≤ 1.5 x upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤ 5 x upper limit of normal in presence of liver metastases, AP ≤ 5 x upper limit of normal * Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal Exclusion Criteria: * Prior chemotherapy * Clinically manifest, uncontrolled brain metastases * Prior radiotherapy of the parameters to be measured * Peripheral neuropathy NCI grade \> 1 * Subject pregnant or breast feeding, or planning to become pregnant within 6 months after the end of treatment. * Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment (adequate: oral contraceptives, intrauterine device or barrier method in conjunction with spermicidal jelly). * Serious concurrent diseases. * Major surgery within the last 4 weeks before recruitment * On-treatment participation in a clinical study in the period 30 days prior to inclusion. * Clinically significant cardiovascular disease in (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment. * Ongoing or active infection, including active tuberculosis or known infection with human immunodeficiency virus. * Superior vena cava syndrome contraindicating hydration. * History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan. * Patient with mild to moderate renal insufficiency who are unable to interrupt salicylates (like aspirin) or other nonsteroidal anti-inflammatory drugs (NSAIDS) for a 5-day period starting 2 days before administration of pemetrexed (8-day period for long-acting agents such as piroxicam). Exception: Low dose aspirin (acetyl salicylic acid) intake up to 150 mg per day is permitted without interruption. * Presence of clinically significant third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures * Inability or unwillingness to take folic acid, vitamin B12 supplementation or dexamethasone (or equivalent corticosteroid); or any other inability to comply with protocol or study related procedures * Prior or concurrent malignancy (≤ 5 years prior to enrolment in study) except non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1 if the patient is continuously disease-free * Known allergic reactions on study medication